Clinical trials: Depression Disorders
Anorexia Nervosa, Eating Disorder
Hormonal Factors in the Treatment of Anorexia Nervosa
The investigators are investigating whether a hormone that is naturally produced by the human body, called testosterone, can help improve weight, disordered eating, depression, and anxiety.
- Conditions
- Anorexia Nervosa, Eating Disorder, Anxiety, Depression
- Trial name
- NCT01121211
- Testing
- Testosterone
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
A Phase 2 Trial of OPC-64005 for Major Depressive Disorder
The objective of the trial is to compare the efficacy of OPC-64005 at 20 mg vs placebo and to assess the safety and pharmacokinetics of OPC-64005 at 10 and 20 mg in patients with major depressive disorder (MDD).The primary…
- Trial name
- NCT04244253
- Testing
- OPC-64005 20 mg , Once-daily, OPC-64005 10 mg , Once-daily
- Where
- Japan
- Volunteers
- 273 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Schizoaffective Disorder, Schizophrenia
Effectiveness of a Mobile Texting Intervention for People With Serious Mental Illness
Testing an mHealth mobile interventionist texting program on illness management.
- Conditions
- Schizoaffective Disorder, Schizophrenia, Bipolar Disorder, Major Depressive Disorder
- Trial name
- NCT03062267
- Testing
- Mobile Interventionist
- Where
- 2 sites in United States
- Volunteers
- 49 people
- Sponsor
- University of Washington
Major Depressive Disorder
A Study of LY2216684 in Healthy Participants
This study will evaluate the pharmacodynamic and pharmacokinetic interaction of LY2216684 with alcohol in healthy participants. This study will run approximately for 34 days.
- Trial name
- NCT01380691
- Testing
- LY2216684, Alcoholic beverage
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Mental Health Issue, Alcohol Use Disorder
Acceptability and Feasibility of Cognitive Behavioral Therapy for Treatment-Seeking (CBT-TS) With Deaf Individuals
The current study aims to assess the acceptability and feasibility of an adapted version of Cognitive Behavioral Therapy for Treatment Seeking (CBT-TS) for use with signing Deaf adults.
- Conditions
- Mental Health Issue, Alcohol Use Disorder, Depression, Anxiety
- Trial name
- NCT05520190
- Testing
- Cognitive Behavioral Therapy for Treatment Seeking (CBT-TS)
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of Rochester
Neonatal Death, Perinatal Death
Leveraging Interactive Text Messaging to Monitor and Support Maternal Health in Kenya
Mobile health (mHealth) interventions such as interactive short message service (SMS) text messaging with healthcare workers (HCWs) have been proposed as efficient, accessible additions to traditional health care in…
- Conditions
- Neonatal Death, Perinatal Death, Depression
- Trial name
- AI-NEO (NCT05369806)
- Testing
- Interactive two-way SMS dialogue
- Where
- 2 sites in Kenya
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Washington
Diabetes, Depression
HOPE Pilot for Veterans With Complex Diabetes
The purpose of this study is to determine if behavioral health coaching for rural veterans with diabetes and depression will improve self-management behaviors and lead to improvement in diabetes care outcomes (e.g., HA1C) and…
- Trial name
- HOPE (NCT01274715)
- Testing
- Behavioral Health Coaching
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Michael E. DeBakey VA Medical Center
Treatment Resistant Depression
KET-RO Plus RO DBT for Treatment Resistant Depression
This pilot study will assess the safety and feasibility of intravenous (IV) ketamine combined with RO DBT in young adults with Treatment-Resistant Depression (TRD).
- Trial name
- KET-RO (NCT06138691)
- Testing
- Ketamine Infusion plus RO DBT
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Washington University School of Medicine
Major Depressive Disorder
Clinical Study of Generic and Brand Bupropion in Depression
Determine bioequivalence between branded and generic bupropion extended release (XL) products (and between generic products) at steady state in patients with major depressive disorder.
- Trial name
- BALANCE (NCT02209597)
- Testing
- Bupropion XL 300
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Washington University School of Medicine
Major Depressive Disorder
A 12-Week, Placebo Controlled Trial of Ziprasidone as Monotherapy for Major Depressive Disorder
This is a study on the effectiveness, tolerability and safety of oral ziprasidone as monotherapy in patients with major depressive disorder (MDD).
- Trial name
- Geodon (NCT00555997)
- Testing
- Ziprasidone
- Where
- 7 sites in United States
- Volunteers
- 120 people
- Sponsor
- Massachusetts General Hospital
Treatment Resistant Depression
A Study in Relapse Prevention of Treatment-Resistant Depression
The purpose of this study is to determine whether olanzapine and fluoxetine combination (OFC) if used for a long time (47 weeks) makes patients suffering from Treatment Resistant Depression stable, determine if OFC is safe when…
- Trial name
- NCT00958568
- Testing
- Olanzapine and Fluoxetine combination (OFC), Fluoxetine
- Where
- 66 sites in United States, Argentina and 6 more
- Volunteers
- 892 people
- Sponsor
- Eli Lilly and Company
Restless Legs Syndrome, Moderate to Severe Idiopathic Restless Legs Syndrome (RLS)
The Effects Of Ropinirole On Mood Or Mild Depression In Patients With Moderate To Severe Restless Legs Syndrome
Ropinirole has shown to improve mood in depressed patients as well as to improve the symptoms of Restless Legs Syndrome. Up to 40% of RLS patients suffer from mild depression, therefore it would be important for decisions no…
- Trial name
- NCT00357097
- Testing
- Ropinirole
- Where
- 50 sites in Germany
- Volunteers
- 240 people
- Sponsor
- GlaxoSmithKline
Depression, Suicidality
Development and Preliminary Trial of a Brief, Portable Health Intervention for Rural Sexual Minority Emerging Adults
The purpose of this study is to test the feasibility of writing interventions specifically designed for lesbian, gay, and bisexual (LGB) emerging adults (ages 18-29) that are aimed at improving the outcomes: depression…
- Conditions
- Depression, Suicidality, Substance Abuse, HIV
- Trial name
- Project LEAP (NCT03751020)
- Testing
- Expressive Writing (EW) Intervention, Self-Affirmation (SA) Intervention, Control
- Where
- 3 sites in United States
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Yale University
Depression, Bipolar
Olanzapine Treatment of Patients With Bipolar I Disorder
The purpose of this study is to assess whether olanzapine is superior to placebo in patients with bipolar depression.
- Trial name
- NCT00510146
- Testing
- Olanzapine
- Where
- 16 sites in China, Japan and 1 more
- Volunteers
- 514 people
- Sponsor
- Eli Lilly and Company
Depression, Major Depressive Disorder
Incomplete Response in Late-Life Depression: Getting to Remission With Buprenorphine
The purposes of this project are to examine the feasibility, safety, tolerability and clinical effect of low-dose buprenorphine as a novel treatment for late-life treatment-resistant depression and to develop preliminary data…
- Trial name
- IRLGREY-B (NCT02176291)
- Testing
- Buprenorphine
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Jordan F. Karp
Major Depressive Disorder (MDD)
Switching From Generic Selective Serotonin Reuptake Inhibitors (SSRIs) and Selective Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) to Three Different Dose Initiation Strategies With Vilazodone
This is an 8-week, randomized, double blind, parallel group, 3-arm trial to compare 10 mg/day, 20 mg/day and 40 mg/day as starting doses of vilazodone following a switch from generic SSRIs and SNRIs.
- Trial name
- NCT02015546
- Testing
- Vilazodone
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Duke University
Treatment Resistant Depressive Disorder
A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression
The purpose of this study is to assess the efficacy and dose response of intranasal esketamine (Panel A: 28 mg, 56 mg, and 84 mg and Panel B: 14 mg and 56 mg) compared with placebo in improving depressive symptoms in participants…
- Trial name
- SYNAPSE (NCT01998958)
- Testing
- Esketamine 14 mg, Esketamine 28 mg, Esketamine 56 mg
- Where
- 25 sites in United States, Belgium and 1 more
- Volunteers
- 108 people
- Sponsor
- Janssen Research & Development, LLC
Post-operative Pain, Respiratory Depression
Dexmedetomidine for the Control of Post-Operative Pain in Thoracotomy Patients
The purpose of this study is to evaluate the safety, efficacy, hemodynamic and respiratory stability of a low-dose of dexmedetomidine infusion in post-operative surgical in-patients undergoing thoracic surgery after discharge…
- Trial name
- NCT00345384
- Testing
- Dexmedetomidine
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Baylor Research Institute
Treatment Resistant Depression
BPL-003 Efficacy and Safety in Treatment Resistant Depression
This is a Phase 2 study randomized, quadruple-masked, multi-center trial with an open-label extension (OLE), designed to investigate the efficacy and safety of BPL-003 in patients with treatment resistant depression (TRD).
- Trial name
- NCT05870540
- Testing
- BPL-003
- Where
- 42 sites in United States, Australia and 4 more
- Volunteers
- 196 people
- Sponsor
- Beckley Psytech Limited
Depression, Anxiety
Efficacy and Feasibility of a Personalized Treatment for Depression With Co-Occurring Anxiety
This study will examine the feasibility and efficacy of a personalized psychotherapy treatment for people with depression and co-occurring anxiety.
- Trial name
- NCT00930293
- Testing
- Interpersonal Psychotherapy for Depression with Panic and Anxiety Symptoms (IPT-PS), Brief Supportive Psychotherapy (BSP), Citalopram hydrobromide
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Pittsburgh